Evaluation of galectin-8 expression in thyroid tumors

被引:12
作者
Savin, S. [1 ]
Cvejic, D. [1 ]
Jankovic, M. [1 ]
Isic, T. [1 ]
Paunovic, I. [2 ]
Tatic, S. [3 ]
机构
[1] Univ Belgrade, Inst Applicat Nucl Energy INEP, Zemun Belgrade 11080, Serbia
[2] Clin Ctr Serbia, Inst Endocrinol Diabet & Dis Metab, Ctr Endocrine Surg, Belgrade 11000, Serbia
[3] Univ Belgrade, Inst Pathol, Fac Med, Belgrade 11000, Serbia
关键词
Thyroid tumors; Immunohistochemical markers; Galectin-8; CELL-ADHESION; BENIGN; CARCINOMA; DIAGNOSIS; TISSUE; MODULATORS; NEOPLASMS; LESIONS; MARKER;
D O I
10.1007/s12032-008-9122-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The expression of galectin-8 (gal-8) has been shown to be altered during neoplastic transformation of certain cell types. This is the first study aimed to analyze the expression of this protein in normal and pathological human thyroid tissue. A total of 41 archival thyroid tissue samples (5 follicular adenomas, 31 papillary carcinomas, 5 follicular carcinomas) together with 36 adjacent hyperplastic or normal thyroid tissues were analyzed by immunohistochemistry. Galectin-8 was expressed in the majority of papillary carcinomas (27/31; 87%). Positive but weaker staining was also found in some of the follicular thyroid carcinomas (2/5; 40%) and adenomas (2/5; 40%). This protein was not detectable in five normal thyroid tissue samples, whereas hyperplastic areas adjacent to tumor were weakly positive in 9 out of 31cases (29%). High gal-8 immunostaining in papillary thyroid carcinoma indicates that gal-8 may potentially serve as a marker of papillary thyroid carcinoma. However, it does not seem to be helpful in the differential diagnostics of follicular carcinoma and adenoma. Further studies are required to determine biological functions and molecular mechanisms underlying the increased expression of gal-8 protein in thyroid lesions, particularly, in papillary thyroid carcinoma.
引用
收藏
页码:314 / 318
页数:5
相关论文
共 32 条
[1]   Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions [J].
Bartolazzi, A ;
Gasbarri, A ;
Papotti, M ;
Bussolati, G ;
Lucante, T ;
Khan, A ;
Inohara, H ;
Marandino, F ;
Orlandi, F ;
Nardi, F ;
Vecchione, A ;
Tecce, R ;
Larsson, O .
LANCET, 2001, 357 (9269) :1644-1650
[2]  
Bassen R, 1999, ANTICANCER RES, V19, P5429
[3]   Human galectin-8 isoforms and cancer [J].
Bidon-Wagner, N ;
Le Pennec, JP .
GLYCOCONJUGATE JOURNAL, 2002, 19 (7-9) :557-563
[4]  
Cvejic D, 1998, ANTICANCER RES, V18, P2637
[5]   Galectins and cancer [J].
Danguy, A ;
Camby, I ;
Kiss, R .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2002, 1572 (2-3) :285-293
[6]  
Danguy A, 2001, HISTOL HISTOPATHOL, V16, P861, DOI 10.14670/HH-16.861
[7]   HISTOLOGICAL-EVALUATION OF THYROID CARCINOMAS - REPRODUCIBILITY OF THE WHO CLASSIFICATION [J].
FASSINA, AS ;
MONTESCO, MC ;
NINFO, V ;
DENTI, P ;
MASAROTTO, G .
TUMORI JOURNAL, 1993, 79 (05) :314-320
[8]   Expression of galectin-3 in normal and malignant thyroid tissue by quantitative PCR and immunohistochemistry [J].
Feilchenfeldt, J ;
Tötsch, M ;
Sheu, SY ;
Robert, J ;
Spiliopoulos, A ;
Frilling, A ;
Schmid, KW ;
Meier, CA .
MODERN PATHOLOGY, 2003, 16 (11) :1117-1123
[9]  
Fernandez PL, 1997, J PATHOL, V181, P80
[10]  
Fischer S, 2008, ARCH PATHOL LAB MED, V132, P359, DOI 10.1043/1543-2165(2008)132[359:AOITTN]2.0.CO